Recent Advances in Immunotherapy in Metastatic NSCLC
Open Access
- 14 November 2016
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 6, 239
- https://doi.org/10.3389/fonc.2016.00239
Abstract
Non-small cell lung cancer (NSCLC) is one of most common malignancies and the leading cause of cancer deaths worldwide. Despite advances in targeted therapies, majority of NSCLC patients do not have targetable genomic alterations. Nevertheless, recent discovery that NSCLC is an immunogenic tumor type, and several breakthroughs in immunotherapies have led to rapid expansion of this new treatment modality in NSCLC with recent FDA approvals of PD-1 inhibitors, nivolumab and pembrolizumab. Here, we review promising immunotherapeutic approaches in metastatic NSCLC, including checkpoint inhibitors, agents with other mechanisms of action, and immunotherapy combinations with other drugs. With advent of immunotherapy, therapeutic options in metastatic NSCLC are rapidly expanding with the hope to further expand life expectancy in metastatic lung cancer.Keywords
Funding Information
- National Cancer Institute (P30 CA118100, P30 CA016672)
- U.S. Department of Defense (LC140074)
This publication has 67 references indexed in Scilit:
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced MelanomaJournal of Clinical Oncology, 2013
- Immunotherapies for non-small-cell lung cancer and mesotheliomaThe Lancet Oncology, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II StudyJournal of Clinical Oncology, 2012
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune EscapeScience Translational Medicine, 2012
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune EscapeCancer Research, 2012
- Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non–Small Cell Lung CancerCancer Discovery, 2011
- Phase I Safety and Pharmacokinetic Study of Bavituximab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients with Advanced Solid TumorsClinical Cancer Research, 2011
- Tumor-infiltrating NY-ESO-1–specific CD8 + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancerProceedings of the National Academy of Sciences of the United States of America, 2010
- Interleukin-2 and Interferon-α in the Treatment of Patients with Advanced Non-Small-Cell Lung CancerJournal of Immunotherapy, 1992